Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b), haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) - injizierbare suspension - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, der rest: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg, kunststoff nein, neomycinum nichts, wasser zu iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

bgp products gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b), haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-stamm b/brisbane/60/2008) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: ovalbuminum max. 0.1 µg, formaldehydum et cetrimidum et polysorbatum 80 et gentamicinum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab dem vollendeten 6. lebensmonat - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - haemagglutininum influenzae a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) 15 µg et neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) 15 µg et neuraminidasum inactivatum (virus-stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b), haemagglutininum influenzae b 15 µg et neuraminidasum inactivatum (virus-stamm b/brisbane/60/2008), adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acidum citricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza für ältere menschen (65 jahre oder älter), besonders für personen mit erhöhtem risiko für influenza-assoziierte komplikationen - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

emergent biosolutions berna gmbh - haemagglutininum influenzae a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) mind.15 µg und neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) mind.15 µg und neuraminidasum inactivatum (virus-stamm a/hong kong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b), haemagglutininum influenzae b mind.15 µg und neuraminidasum inactivatum (virus-stamm b/brisbane/60/2008), natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesium, chloridum hexahydricum, calcium chloridum dihydricum, wasser ad iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza, ab dem vollendeten 6. lebensmonat - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ), haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/hong kong/4801/2014 (h3n2)-like: reassortant virus nymc x-263b ) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/brisbane/60/2008 (victoria lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

paxvax berna gmbh - haemagglutininum influenzae a (h1n1), neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) mind.15 µg et neuraminidasum inactivatum (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) mind.15 µg et neuraminidasum inactivatum (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186), haemagglutininum influenzae b mind.15 µg et neuraminidasum inactivatum (virus-stamm b/colorado/06/2017)-like: reassortant virus b/victoria/2/87_b/maryland/15/2016), adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acidum citricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza für ältere menschen (65 jahre oder älter), besonders für personen mit erhöhtem risiko für influenza-assoziierte komplikationen - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

glaxosmithkline ag - haemagglutininum influenzae a (h1n1) (virus-stamm a/michigan/45/2015 (h1n1)-like: reassortanten virus ivr-180, abgeleitet von a/singapore/gp1908/2015), haemagglutininum influenzae a (h3n2) (virus-stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus-feder-104 ), haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata-linie)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus stamm a/michigan/45/2015 (h1n1)-like: reassortant virus ivr-180 derived from a/singapore/gp1908/2015) 15 µg, haemagglutininum influenzae a (h3n2) (virus stamm a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus nib-104 ) 15 µg, haemagglutininum influenzae b (virus stamm b/colorado/06/2017-like: reassortant virus b/maryland/15/2016 nymc bx-69a (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, polysorbatum 80, octoxinolum-10, natrii chloridum, magnesii chloridum hexahydricum, dinatrii phosphas dodecahydricus, kalii dihydrogenophosphas, kalii chloridum, alfa-tocopheroli hydrogenosuccinas, residui: ovalbuminum max. 0.05 µg, formaldehydum max. 5 µg, natrii desoxycholas max. 65 µg, gentamicini sulfas nihil, hydrocortisonum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab 36 monaten - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

medius ag - haemagglutininum influenzae a (h1n1), neuraminidasum inactivatum (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018), haemagglutininum influenzae a (h3n2), haemagglutininum influenzae b - injektionssuspension - haemagglutininum influenzae a (h1n1) mind.15 µg und neuraminidasum inactivatum (virus-stamm a/brisbane/02/2018 (h1n1)-like: reassortanten virus ivr-190, abgeleitet von a/brisbane/02/2018), haemagglutininum influenzae a (h3n2) mind.15 µg und neuraminidasum inactivatum (virus-stamm a/kansas/14/2017 (h3n2)-like: reassortanten virus x-327, abgeleitet von a/kansas/14/2017), haemagglutininum influenzae b mind.15 µg und neuraminidasum inactivatum (virus-stamm b/colorado/06/2017)-wie: reassortanten viren der b/victoria/2/87_b/maryland/15/2016), adjuvans mf59: squalenum, polysorbatum 80, sorbitani trioleas, natrii citras dihydricus, acid citricum, excipiens: natrii chloridum, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesium, chloridum hexahydricum, calcium chloridum dihydricum, der rest: ovalbuminum, barii sulfas, kanamycini monosulfas, neomycini sulfas, formaldehydum, cetrimidum, hydrocortisonum, aqua ad iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza für ältere menschen (65 jahre oder älter), besonders für personen mit erhöhtem risiko für influenza-assoziierte komplikationen - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-19 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus souche b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Switzerland - Jerman - Swissmedic (Swiss Agency for Therapeutic Products)

mylan pharma gmbh - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019), haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019), haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) - injektionssuspension - haemagglutininum influenzae a (h1n1) (virus-stamm a/guangdong-maonan/swl1536/2019 (h1n1)-pdm09: reassortant virus cnic-1909 derived from a/guangdong-maonan/swl1536/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus-stamm a/hong kong/2671/2019 (h3n2)-like: reassortant virus ivr-208 derived from a/hong kong/2671/2019) 15 µg, haemagglutininum influenzae b (virus-stamm b/washington/02/2019 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus-stamm b/phuket/3073/2013 (yamagata lineage)) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 2.0 mg, kalium 0.1 mg, residui: cetrimidum, formaldehydum, gentamicini sulfas, polysorbatum 80, ovalbuminum. - aktive immunisierung gegen influenza, ab 3 jahren - impfstoffe